Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure
Published: abril 26, 2017
- The role of biomarkers in the management of heart failure (HF) is discussed in this AHA Scientific Statement.
- HF is a complex syndrome with diverse pathways and pathologic processes that can manifest in circulation as biomarkers.
- Many biomarkers are now clinically available that can provide diagnostic and prognostic information regarding HF.
Recommended Reading
- Current diagnostic and treatment strategies for specific dilated cardiomyopathies
- Contributory Risk Management of Comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia and metabolic syndrome in chronic heart failure
- Drugs that may cause or exacerbate heart failure
- 2016 ACC/AHA/HFSA Focused Update on New Pharmacological therapy for HF: an update of the 2013 ACCF/AHA Guidelines for the Management of Heart Failure